Strategic Financial Services Inc. lowered its position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 8.5% during the 4th quarter, Holdings Channel.com reports. The firm owned 260,924 shares of the exchange traded fund’s stock after selling 24,213 shares during the period. SPDR S&P Biotech ETF accounts for 1.5% of Strategic Financial Services Inc.’s investment portfolio, making the stock its 16th largest holding. Strategic Financial Services Inc.’s holdings in SPDR S&P Biotech ETF were worth $32,749,000 at the end of the most recent reporting period.
Several other large investors have also added to or reduced their stakes in XBI. Dynamic Wealth Strategies LLC lifted its holdings in shares of SPDR S&P Biotech ETF by 3.8% in the fourth quarter. Dynamic Wealth Strategies LLC now owns 2,201 shares of the exchange traded fund’s stock worth $268,000 after buying an additional 80 shares in the last quarter. Capital Investment Advisory Services LLC lifted its holdings in shares of SPDR S&P Biotech ETF by 4.0% in the fourth quarter. Capital Investment Advisory Services LLC now owns 2,123 shares of the exchange traded fund’s stock worth $259,000 after buying an additional 81 shares in the last quarter. Compass Ion Advisors LLC lifted its holdings in shares of SPDR S&P Biotech ETF by 2.6% in the fourth quarter. Compass Ion Advisors LLC now owns 3,886 shares of the exchange traded fund’s stock worth $474,000 after buying an additional 97 shares in the last quarter. Moors & Cabot Inc. lifted its holdings in shares of SPDR S&P Biotech ETF by 3.8% in the third quarter. Moors & Cabot Inc. now owns 2,717 shares of the exchange traded fund’s stock worth $272,000 after buying an additional 100 shares in the last quarter. Finally, Sequoia Financial Advisors LLC lifted its holdings in shares of SPDR S&P Biotech ETF by 3.1% in the third quarter. Sequoia Financial Advisors LLC now owns 3,393 shares of the exchange traded fund’s stock worth $340,000 after buying an additional 101 shares in the last quarter.
SPDR S&P Biotech ETF Stock Performance
XBI stock opened at $133.35 on Wednesday. SPDR S&P Biotech ETF has a one year low of $78.06 and a one year high of $139.19. The company’s fifty day moving average price is $130.23 and its 200-day moving average price is $125.49. The company has a market capitalization of $8.51 billion, a PE ratio of 11.47 and a beta of 0.85.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
Read More
- Five stocks we like better than SPDR S&P Biotech ETF
- Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
- AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
